This study investigates the efficiency of the new CDF appraisal process for indications without prio...
Read moreThis study investigates NICE's evaluation of existing CDF treatments and its potential impact on fun...
Read moreIncluded in this issue is the implications for the UK market regarding Brexit and how the UKs CDF pe...
Read moreThis process aims to be completely transparent , to enable faster patient access to oncology treatme...
Read moreBoth payers and physicians do not believe that at the current prices Praluent and Repatha offer sign...
Read morePharma companies must start preparing its NICE submission at the time of making the regulatory subm...
Read moreTopics include our perspectives on an EU commission report on how international reference pricing ca...
Read moreFrom July 2016 NICE will gain decision power by saying yes, no or maybe to cancer drugs entering the...
Read moreThe proposal states that the CDF should become a "managed access" fund for new cancer dugs, with cle...
Read moreIn this issue is an overview of the future changes to the UK Cancer Drug Fund as well as approaches ...
Read more